Better predict pharmacokinetic (PK) and drug-drug interactions (DDIs) with DMPK/ADME studies and computational modeling on your compound, prior to clinical trials, to move quickly from discovery to development.
Drug-Drug Interaction (DDI) sample analysis
Dose range finding (DRF) sample analysis
Dried Blood Spot (DBS) sample analysis
Pharmacology (PK) sample analysis
Toxicology (TK) / safety sample analysis
Environmental risk assessment (ERA)
OPPTS 860.1300: Nature of the residue in plants, livestock
OPPTS 870.7600: Dermal penetration
Physiologically based pharmacokinetics (PBPK) modeling
Quantitative and/or systems pharmacology (QSP/SP) modeling
Pharmacokinetic/pharmacodynamic (PK/PD) modeling
Compartmental & non-compartmental PK/TK analysis
Bioavailability, bioequivalence and biosimilars modeling
In vivo pharmacokinetics (PK)
Enzyme inhibition for drug-drug interaction (DDI) investigations
Consider the integration possibilities between your preclinical and clinical studies
As an integrated preclinical & clinical CRO, we can offer you connected insights between your nonclinical pharmacology work and your clinical pharmacology studies and clinical trials.
For example, some PBPK pharmacometrics have been accepted in lieu of clinical DDI studies.
Let's start a conversation
Contact Us
Labcorp is a leading global life sciences company that includes contract research and developmental services to the pharmaceutical, medical technology, crop protection and chemical industries.
.png){kind=icon}